

17 Oct 2021 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: US tax policies challenge pharma; J&J's long-time R&D head to retire; Legend Biotech's CEO talks about plans; BMS disappointment in ulcerative colitis; and another gene therapy partnership for Takeda.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 15 October 2021, including: US tax policies challenge pharma; [*Johnson & Johnson's*](#) long-time R&D head to retire; [*Legend Biotech Corp.*](#)'s CEO talks about plans; [*Bristol Myers Squibb Company*](#) disappointment in ulcerative colitis; and another gene therapy partnership for [*Takeda Pharmaceutical Co. Ltd.*](#)

This and all our other podcasts are available on the Informa Pharma Intelligence channel on [*Apple Podcasts*](#), [*Google Podcasts*](#), [*SoundCloud*](#), [*TuneIn*](#) and [*Spotify Podcasts*](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[*Under The Shadow Of Drug Price Reform, US Tax Policies Still Challenge Pharma*](#)" - Scrip, 12 Oct, 2021.)

(Also see "[*J&J's Longtime R&D Head Stoffels To Retire, Raising The Leadership Transition Stakes*](#)" - Scrip, 12 Oct, 2021.)

(Also see "[*As Cilta-Cel's Big Day Approaches, Legend Looks Beyond Myeloma*](#)" - Scrip, 8 Oct, 2021.)

(Also see "[*Bristol's High Profile TYK2 Inhibitor Disappoints In Ulcerative Colitis*](#)" - Scrip, 7 Oct, 2021.)

SCRIP

CITELINE COMMERCIAL

(Also see "[Takeda Continues Recent Gene Therapy Partnering Spree With Poseida Pact](#)" - Scrip, 12 Oct, 2021.)

[Click here to explore this interactive content online](#) 